In this article published in the Spring 2015 edition of Public Domain, the ABA Section of Antitrust Law Intellectual Property Committee newsletter, Nicole Callan discusses "product hopping," a practice in which brand manufacturers launch a new version of a successful drug before generic drug companies can enter the market with generic versions.
We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.
